These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 14509921)

  • 1. Exploitation of prostate gene expression to develop targeted therapies.
    Maitland NJ
    Acta Biomed; 2003 Aug; 74(2):105-6. PubMed ID: 14509921
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting therapeutic gene expression to human prostate cancers.
    Maitland NJ
    Curr Opin Mol Ther; 2000 Aug; 2(4):389-99. PubMed ID: 11249769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for prostate cancer.
    Bower M; Waxman J
    Semin Cancer Biol; 1997 Feb; 8(1):3-9. PubMed ID: 9299576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter.
    Yu D; Jia WW; Gleave ME; Nelson CC; Rennie PS
    Prostate; 2004 Jun; 59(4):370-82. PubMed ID: 15065085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer.
    Lu Y
    Adv Drug Deliv Rev; 2009 Jul; 61(7-8):572-88. PubMed ID: 19393705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
    Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
    Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy approach in prostate cancer cells using an active Wnt signal.
    Giladi N; Dvory-Sobol H; Sagiv E; Kazanov D; Liberman E; Arber N
    Biomed Pharmacother; 2007 Oct; 61(9):527-30. PubMed ID: 17904788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
    Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
    Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene.
    Yu W; Pirollo KF; Rait A; Yu B; Xiang LM; Huang WQ; Zhou Q; Ertem G; Chang EH
    Gene Ther; 2004 Oct; 11(19):1434-40. PubMed ID: 15229629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.
    Kaliberov SA; Kaliberova LN; Buchsbaum DJ
    Gene Ther; 2005 Mar; 12(5):407-17. PubMed ID: 15616600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
    Kraaij R; van der Weel L; de Ridder CM; van der Korput HA; Zweistra JL; van Rijswijk AL; Bangma CH; Trapman J
    Prostate; 2007 Jun; 67(8):829-39. PubMed ID: 17394196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different approaches of gene therapy used in prostate cancer.
    Ghosh A
    Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(1):103-11. PubMed ID: 16171569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate.
    Fullerton NE; Boyd M; Mairs RJ; Keith WN; Alderwish O; Brown MM; Livingstone A; Kirk D
    Prostate Cancer Prostatic Dis; 2004; 7(4):355-63. PubMed ID: 15477875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells.
    Peng W; Chen J; Huang YH; Sawicki JA
    Gene Ther; 2005 Nov; 12(21):1573-80. PubMed ID: 16034457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice.
    Lee J; Wang A; Hu Q; Lu S; Dong Z
    Int J Oncol; 2006 Dec; 29(6):1405-12. PubMed ID: 17088978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.
    Thorne SH; Tam BY; Kirn DH; Contag CH; Kuo CJ
    Mol Ther; 2006 May; 13(5):938-46. PubMed ID: 16469543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy of prostate xenograft tumors with a p75NTR lipoplex.
    Allen J; Khwaja F; Djakiew D
    Anticancer Res; 2004; 24(5A):2997-3003. PubMed ID: 15517907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
    Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
    Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro.
    Marignol L; Foley R; Southgate TD; Coffey M; Hollywood D; Lawler M
    J Gene Med; 2009 Feb; 11(2):169-79. PubMed ID: 19051213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
    Lee SJ; Zhang Y; Lee SD; Jung C; Li X; Kim HS; Bae KH; Jeng MH; Kao C; Gardner T
    Mol Ther; 2004 Dec; 10(6):1051-8. PubMed ID: 15564137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.